Welcome to our dedicated page for Deciphera Pharma news (Ticker: DCPH), a resource for investors and traders seeking the latest updates and insights on Deciphera Pharma stock.
Deciphera Pharmaceuticals (DCPH) is a biotechnology innovator advancing targeted therapies for cancer through its expertise in kinase inhibition. This page provides investors and industry professionals with verified updates on the company's clinical developments, regulatory milestones, and strategic initiatives.
Access real-time announcements including quarterly earnings reports, FDA filings, clinical trial data, and partnership agreements. Our curated collection ensures you stay informed about DCPH's progress in developing small molecule therapeutics, particularly following its integration with Ono Pharmaceutical's global oncology network.
Key updates cover research breakthroughs, pipeline advancements, and operational developments within the company's Boston and Kansas research hubs. Bookmark this page for direct access to primary source materials and objective analysis of Deciphera's position in the competitive oncology therapeutics landscape.
Deciphera Pharmaceuticals (NASDAQ: DCPH) has priced an underwritten public offering of 5,251,239 shares at $10.00 per share and pre-funded warrants for 9,748,761 shares at $9.99 each. The total gross proceeds are estimated at $150 million, before expenses. The offering is set to close on April 29, 2022. Proceeds will fund the development of vimseltinib for tenosynovial giant cell tumor patients, DCC-3116 combination studies, and the pan-RAF program, along with general working capital needs. J.P. Morgan and Jefferies are the joint book-running managers.
Deciphera Pharmaceuticals (NASDAQ: DCPH) plans to raise $150 million through an underwritten public offering of common stock and pre-funded warrants. The offering includes a 30-day option for underwriters to purchase an additional $22.5 million in shares. Funds will support the development of vimseltinib in a Phase 3 study for TGCT, clinical trials for DCC-3116, the pan-RAF program, and general working capital. The securities are offered under an effective registration statement, with J.P. Morgan and Jefferies acting as joint book-running managers.
Deciphera Pharmaceuticals announced promising preclinical data for DCC-3116, a ULK kinase inhibitor, in combination with KRASG12C inhibitors for non-small cell lung cancer (NSCLC). Presented at the AACR Annual Meeting 2022, results indicated that DCC-3116, when paired with sotorasib or adagrasib, achieved deeper and longer tumor regressions compared to these inhibitors alone. The data highlights DCC-3116's potential in overcoming drug resistance through autophagy inhibition. Further clinical trials are anticipated to confirm these findings.
Deciphera Pharmaceuticals (NASDAQ: DCPH) announced that Tucker Kelly, CFO, will participate in a fireside chat at the Barclays Global Healthcare Conference on March 16, 2022, at 4:20 PM ET in Miami. A live webcast will be available on Deciphera’s Investors page, with a replay archived for 90 days. Deciphera is focused on developing innovative medicines for cancer treatment, utilizing its unique switch-control kinase inhibitor platform. Their product, QINLOCK®, is approved in several markets, including the U.S. and Europe, for treating fourth-line GIST.
Deciphera Pharmaceuticals reported Q4 2021 revenue of $24.2 million, with a total of $96.1 million for the year. The company is launching QINLOCK® in Europe and progressing two pivotal clinical studies: MOTION for vimseltinib and initial DCC-3116 data expected in 2H 2022. Despite a net loss of $88.4 million in Q4, cash reserves totaled $327.6 million. Challenges include the restructuring and disappointing results from the INTRIGUE study, which did not meet its primary endpoint.
Deciphera Pharmaceuticals (NASDAQ: DCPH) announced that CEO Steve Hoerter will present at two upcoming investor conferences: the Guggenheim 2022 Oncology Virtual Conference on February 9, 2022, at 8:30 AM ET and the 11th Annual SVB Leerink Global Healthcare Conference on February 16, 2022, at 3:40 PM ET. Live webcasts of both events will be available on the company's website, with replays accessible for 90 days post-presentation. Deciphera focuses on developing innovative cancer treatments, including its approved QINLOCK® for fourth-line GIST in various regions, including the U.S.
Deciphera Pharmaceuticals (NASDAQ: DCPH) will release its fourth quarter and full year 2021 financial results on February 8, 2022, followed by a live conference call at 4:30 PM ET. Interested parties can join the call by dialing (866) 930-5479 or accessing the webcast on the company’s website. Deciphera focuses on developing innovative cancer therapies, including QINLOCK®, approved in several regions worldwide for treating fourth-line GIST.
Deciphera Pharmaceuticals (DCPH) has presented results from the INTRIGUE Phase 3 study of QINLOCK in GIST patients, showing that ripretinib's efficacy is comparable to sunitinib, although it did not meet its primary endpoint for superiority in progression-free survival (PFS). The study involved 453 patients and highlighted that ripretinib had a better safety profile, with fewer severe adverse events. Notably, the objective response rate for ripretinib was 23.9% in patients with KIT exon 11 mutations, outperforming sunitinib's 14.6%. QINLOCK remains approved for use in multiple regions.
Deciphera Pharmaceuticals (NASDAQ: DCPH) has highlighted significant milestones for 2022 during its presentation at the J.P. Morgan Healthcare Conference. The company is launching QINLOCK in Germany and transitioning to a paid access program in France. Key clinical programs include the Phase 3 MOTION study for vimseltinib in tenosynovial giant cell tumor patients and ongoing developments for DCC-3116, a novel kinase inhibitor. Results from pivotal studies are expected to be presented in 2022, underscoring the company's commitment to improving cancer treatment options.
Deciphera Pharmaceuticals (NASDAQ: DCPH) will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 9:00 AM ET. The event will be accessible via live webcast on their website's "Events and Presentations" page. A replay will be available for 30 days post-event. Deciphera specializes in developing innovative cancer treatments, with QINLOCK approved in several regions including the US, EU, and Australia. For more details, visit www.deciphera.com.
